{"a":[{"_":"Amgen’s DLL3-targeted Imdelltra scores overall survival win in first-line small cell lung cancer","$":{"href":"/pharma/amgen-dll3-targeted-imdelltra-scores-overall-survival-win-first-line-small-cell-lung-cancer","hreflang":"en"}}]}
Data ReadoutpositiveImdelltraPositive
AI Analysis
Summary
Amgen's DLL3-targeted bispecific antibody Imdelltra achieved an overall survival win in first-line small cell lung cancer. The company indicated the data suggest Imdelltra will advance the treatment standard earlier in the disease journey.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Overall survival win in first-line small cell lung cancer
Importance:8/10
Sentiment:
0.80
oncologysmall cell lung cancerDLL3-targetedbispecificoverall survivalclinical trial results
Related Companies
Read the original article
Published by FiercePharma on September 8, 2026 11:14 AM